Valeritas Holdings, Inc. announced the positive results of five retrospective analyses of the clinical and cost benefits of the company’s lead product, the V-Go Disposable Insulin Delivery device. The data were disclosed in five posters presented at the American Association of Clinical Endocrinologists’ (AACE) 25th Annual Scientific and Clinical Conference in Orlando, FL, last week.
The studies showed that when using, or switching to V-Go, patients with diabetes experienced improved glycemic control, a reduction in A1C, and required less insulin than the comparison treatments.
“The posters presented at AACE clearly support the overall effectiveness of V-Go as an insulin delivery method for patients with Type 2 diabetes from a variety of perspectives,” according to said Dr. David Sutton, endocrinologist, co-founder of Northeast Florida Endocrine & Diabetes Associates, and an author of two of the study posters listed below.
“Referring to the studies in which I was personally involved, the data provides further real-world clinical evidence that using V-Go results in improved glycemic control and a reduction in total daily insulin doses,” Sutton added. “In addition, it was demonstrated that total insulin therapy costs less when using regular insulin with V-Go. This is significant as cost is truly a challenge for patients today.”
Small, Discreet, Wearable
V-Go is a small, discreet, wearable disposable insulin delivery device for the delivery of basal-bolus insulin therapy in adults with Type 2 diabetes. It enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery by releasing a single type of insulin at a continuous preset basal rate over a 24-hour period and also providing for on-demand bolus dosing at mealtimes.
The device is mechanical and operates for 24 hours without electronics, batteries, infusion sets or programming. It is worn on the skin under clothing and measures just 2.4 inches wide by 1.3 inches long by 0.5 inches thick, weighing approximately one ounce when filled with insulin.
Following are the five posters that were presented at the conference:
— Comparison of Two Methods for Intensified Insulin Delivery on Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin (Rosemarie Lajara, MD, et al).
— Decreased Frequency of Hypoglycemia and Improved Glycemic Control in Patients With T2DM Pre- and Post-Initiation of a Disposable Insulin Delivery Device (Rebecca Ray, MSN, APRN, FNP-C).
— Regular Insulin Administered With the V-Go Disposable Insulin Delivery Device in a Clinical Diabetes Setting: A Retrospective Analysis of Efficacy and Cost (David Sutton, MD, et al).
— Evaluating the Impact of Diabetes Control With V-Go for Patients Within a High Risk Population: A Retrospective Cohort Analysis from a Large Endocrine and Specialized Diabetes System (David Sutton, MD, et al).
— Optimizing Insulin Therapy in Older Adults in the Long-Term Care Setting: An Efficacy and Safety Comparator Analysis (Alan Boonin, MD, et al).
